111 And Scrianen Forge Strategic Partnership To Enhance Drug Supply And Accessibility Across China

6/11/24 4:24:36 AM ET

Retail-Drug Stores and Proprietary Stores

Consumer Staples

Get the next $YI alert in real time by email

111, Inc. leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, announced that the Company has entered into a strategic direct supply partnership (the "Partnership") with Beijing Scrianen Pharmaceutical Co., Ltd. ("Scrianen"), a comprehensive pharmaceutical enterprise that integrates research and development, production and marketing.

Get the next $YI alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$YI

Date	Price Target	Rating	Analyst

More analyst ratings

$YI
Leadership Updates

Live Leadership Updates

111, Inc. Announces Change to Board of Directors
SHANGHAI, Nov. 4, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that Dr. Leon Lian Yong Chen has tendered his resignation from the position as the Company's director for personal reasons, effective on November 4, 2024. The board has also appointed Mr. Yang "Luke" Chen, currently serving as the Company's Senior Finance Executive, as a new director, effective November 4, 2024. Dr. Lian Yong Chen has served on the board of directors of the Company since May 2019. "I am grateful to Dr
11/4/24 5:00:00 AM ET
$YI
Retail-Drug Stores and Proprietary Stores
Consumer Staples
111 Announces Appointment of New Auditor
SHANGHAI, July 19, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced the appointment of Grant Thornton Zhitong Certified Public Accountants LLP ("Grant Thornton") as the Company's independent registered public accounting firm, effective July 19, 2024, replacing Deloitte Touche Tohmatsu Certified Public Accountants LLP. The change of the Company's independent registered public accounting firm was made after a careful and thorough evaluation process and has been approved by 111's boar
7/19/24 8:45:00 AM ET
$YI
Retail-Drug Stores and Proprietary Stores
Consumer Staples
111, Inc. Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee
SHANGHAI, Sept. 23, 2022 /PRNewswire/ -- 111, Inc. ( "111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company in China, announced today that the special committee (the "Special Committee"), consisting of three independent directors, Mr. Jian Sun, who is the chairman of the Special Committee, Mr. Nee Chuan Teo and Mr. Jun Luo, established by the Company's Board of Directors (the "Board") has retained Houlihan Lokey China Limited as its independent financial advisor and Kirkland & Ellis as its U.S. legal counsel in connection with its review and evaluation of the previously announced preliminary non-binding proposal letter dated September 9, 2022 (the "Proposal")
9/23/22 12:30:00 AM ET
$YI
Retail-Drug Stores and Proprietary Stores
Consumer Staples

111, Inc. to Participate in Fireside Chat with Water Tower Research on December 6, 2024
SHANGHAI, Nov. 21, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that it will participate in a fireside chat with Robert Sassoon, senior research analyst at Water Tower Research ("WTR") on Friday, December 6, 2024 at 11:00 a.m. ET. Mr. Junling Liu, Co-Founder, Chairman, and Chief Executive Officer of 111, will discuss the Company's Q3 2024 earnings (to be reported on Wednesday, November 27, 2024), along with challenges, opportunities, and the NASDAQ share price compliance issue. T
11/21/24 5:00:00 AM ET
$YI
Retail-Drug Stores and Proprietary Stores
Consumer Staples
111 Reschedules Third Quarter 2024 Unaudited Financial Results Announcement to November 27, 2024 - Conference Call to Follow
SHANGHAI, Nov. 4, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that its release of unaudited financial results for the third quarter ended September 30, 2024, previously scheduled for Thursday, November 28, 2024, will now occur before the U.S. market opens on Wednesday, November 27, 2024. 111's management team will host an earnings conference call at 7:30 AM U.S. Eastern Time on Wednesday, November 27, 2024 (8:30 PM Beijing Time on the same day). Details for the conference call a
11/4/24 6:00:00 AM ET
$YI
Retail-Drug Stores and Proprietary Stores
Consumer Staples
111, Inc. Announces Change to Board of Directors
SHANGHAI, Nov. 4, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that Dr. Leon Lian Yong Chen has tendered his resignation from the position as the Company's director for personal reasons, effective on November 4, 2024. The board has also appointed Mr. Yang "Luke" Chen, currently serving as the Company's Senior Finance Executive, as a new director, effective November 4, 2024. Dr. Lian Yong Chen has served on the board of directors of the Company since May 2019. "I am grateful to Dr
11/4/24 5:00:00 AM ET
$YI
Retail-Drug Stores and Proprietary Stores
Consumer Staples

$YI
Financials

Live finance-specific insights

111 Reschedules Third Quarter 2024 Unaudited Financial Results Announcement to November 27, 2024 - Conference Call to Follow
SHANGHAI, Nov. 4, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that its release of unaudited financial results for the third quarter ended September 30, 2024, previously scheduled for Thursday, November 28, 2024, will now occur before the U.S. market opens on Wednesday, November 27, 2024. 111's management team will host an earnings conference call at 7:30 AM U.S. Eastern Time on Wednesday, November 27, 2024 (8:30 PM Beijing Time on the same day). Details for the conference call a
11/4/24 6:00:00 AM ET
$YI
Retail-Drug Stores and Proprietary Stores
Consumer Staples
111 to Announce Third Quarter 2024 Unaudited Financial Results on November 28, 2024 - Conference Call to Follow
SHANGHAI, Oct. 18, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2024, before the U.S. market opens on Thursday, November 28, 2024. 111's management team will host an earnings conference call at 7:30 AM U.S. Eastern Time on Thursday, November 28, 2024 (8:30 PM Beijing Time on the same day). Details for the conference call are as follows: Conference Topic: 111, Inc. Third Quarter 2024 Earn
10/18/24 5:00:00 AM ET
$YI
Retail-Drug Stores and Proprietary Stores
Consumer Staples
111, Inc. Announces Second Quarter 2024 Unaudited Financial Results
Maintained Operational Profitability for the Second Consecutive QuarterOperating Expenses as a Percentage of Revenues Decreased 120 Basis Points YoYHeld Positive Operating Cash Flow for Two Consecutive QuartersSHANGHAI, Aug. 29, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Highlights Net revenues were RMB3.4 billion (US$471.2 million) and gross segment profit (1) was RMB 207.6 million
8/29/24 2:00:00 AM ET
$YI
Retail-Drug Stores and Proprietary Stores
Consumer Staples

111 And Scrianen Forge Strategic Partnership To Enhance Drug Supply And Accessibility Across China

Chat with this insight

Recent Analyst Ratings for
$YI

$YI
Leadership Updates

Live Leadership Updates

111, Inc. Announces Change to Board of Directors

111 Announces Appointment of New Auditor

111, Inc. Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee

$YI
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Citigroup resumed coverage on 111, Inc. with a new price target

$YI
Market Insights

Live Market Insights

CORRECTION: 111 Reported Strategic Partnership On June 11

111 shares are trading higher after the company announced that it entered into a strategic direct supply partnership with Beijing Scrianen Pharmaceutical.